this page only  
Join BIO   |   Member Directory   |    Contact BIO    
Biotechnology Industry Organization

Home
About BIO
Conferences & Events
Past BIO Events
Industry Calendar
State/Int'l Calendar
Members.BIO.org
BIO News Online
BIO Bulletins
Suggestion Box
Membership Directory
BIO Videos
News & Media
BIO Blogs & Podcasts
National Issues
Health
Food & Agriculture
Industrial & Environmental
Bioethics
Intellectual Property
Regulatory
Tax & Financial
State & Local Issues
State by State Initiatives
Letters, Testimony & Comments
Speeches & Publications
Industry At-a-Glance
Business & Finance
BIO News


Sunday, November 22, 2009

Scientists Get Closer to Stem-Cell Treatments for Parkinson's Patients

Click here for a printer-friendly page Printer Friendly

June 13, 2007

New research published yesterday in the Proceedings of the National Academy of Sciences by researchers from Yale University in Connecticut, suggests that injection of human neural stem cells directly into the brains of monkeys may one day lead to similar treatments for human Parkinson's patients.

The scientists induced Parkinson's symptoms in monkeys. Some of the symptoms were so severe that the monkeys had difficulty walking, showed very little movement, slowed movement responses. Then the scientists injected the monkeys with human neural stem cells. The monkeys were followed for sixty days. Monkeys that received stem cell injections improved significantly compared to the controls. The researchers noticed improvement in areas such as the ability to sit, walk, feed oneself.

The researchers then tried to determine where exactly the stem cells had gone. It turned out that they all went and did different things. But says, Eugene Redmond, lead author on the paper, they all stayed within the dopanergic system. Before this research gets to the clinic says Redmond they need to study the animals for longer, at least 18 months to two years. The good new in the short term is that none of the animals in this study developed tumors. The bad news is that outside of embryonic stem cell transfer developing a new treatment drug will be very difficult, because the cells that are being lost, are the cells that that are required to process the drug treatment.


Signals that control body movements travel along neurons that project from the substantia nigra to the caudate nucleus and putamen (collectively called the striatum). These "nigro-striatal" neurons release dopamine at their stargets in the striatum. In Parkinson's patients, dopamine neurons in the nigro-striatal pathway degenerate for unknown reasons. credit: NIH

contact us | terms of use | privacy policy
© 2009 | Biotechnology Industry Organization | 1201 Maryland Ave., SW, Ste. 900 | Washington, D.C. 20024